9-substituted minocycline compounds
View Patent ↗The present invention pertains, at least in part, to novel 9-substituted minocycline compounds. These minocycline compounds can be used to treat numerous tetracycline compound-responsive states, such as bacterial infections and neoplasms, as well as other known applications for minocycline and tetracycline compounds in general, such as blocking tetracycline efflux and modulation of gene expression.
1. A minocycline compound of formula I:
wherein:
X is CHC(R 13 Y′Y), CR 6′ R 6 , S, NR 6 , or O;
R 2 , R 4′ , R 4″ , R 7′ and R 7″ are each hydrogen, altyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, alkylamino, arylalkyl, aryl, heterocyclic, heteroaromatic or a prodrug moiety;
R 4 is NR 4′ R 4″ , alkyl, alkenyl, alkynyl, aryl, hydroxyl, halogen, or hydrogen;
R 2′ , R 3 , R 10 , R 11 and R 12 are each hydrogen or a pro-drug moiety;
R 5 is hydroxyl, hydrogen, thiol, alkanoyl, aroyl, alkaroyl, aryl, heteroaromatic, alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, alkylamino, arylalkyl, alkyl carbonyloxy, or aryl carbonyloxy;
R 6 and R 6′ are independently hydrogen, methylene, absent, hydroxyl, halogen, thiol, alkyl, alkenyl, alkynyl, aryl, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, alkylamino, or an arylalkyl;
R 9 is alkynyl substituted with an alkyl group;
R 8 is hydrogen, hydroxyl, halogen, thiol, alkyl, alkenyl, alkynyl, aryl, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, alkylamino, or an arylalkyl;
R 13 is hydrogen, hydroxy, alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, alkylamino, or an arylalkyl;
Y′ and Y are each independently hydrogen, halogen, hydroxyl, cyano, sulfhydryl, amino, alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, alkylamino, or an arylalkyl, and pharmaceutically acceptable salts, esters and prodrugs thereof.
2. The minocycline compound of claim 1 , wherein it R 4 is NR 4′ R 4″ ; X is CR 6 R 6′ ; R 2 , R 2′ , R 5 , R 6 , R 6′ , R 8 , R 9 , R 10 , R 11 , and R 12 are each hydrogen; and, R 4′ , R 4″ , R 7′ , and R 4″ are each lower alkyl.
3. The minocycline compound of claim 2 , wherein R 4′ , R 4″ , R 7′ , and R 7″ are each methyl.
4. The minocycline compound of claim 1 , wherein said alkyl substituent is aminoalkyl.
5. The minocycline compound of claim 4 , wherein said aminoalkyl is substituted with a alkylsulfonamide group.
6. A minocycline compound or a pharmaceutically acceptable salt thereof of the formula:
7. The minocycline compound of claim 6 , wherein said minocycline compound is.
8. The minocycline compound of claim 1 , wherein R 9 is alkynyl substituted with a straight-chain alkyl group.
9. The minocycline compound of claim 8 , wherein said straight-chain alkyl group is methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, nonyl, or decyl.
10. The minocycline compound of claim 1 , wherein R 9 is alkynyl substituted with a branched-chain alkyl group.
11. The minocycline compound of claim 10 , wherein said branched-chain alkyl group is isopropyl, tert-butyl, or isobutyl.
12. The minocycline compound of claim 1 , wherein R 9 is alkynyl substituted with a cycloalkyl group.
13. The minocycline compound of claim 12 , wherein said cycloalkyl group is cyclopropyl, cyclopentyl, cyclohexyl, cycloheptyl, or cyclooctyl.
14. The minocycline compound of claim 1 , wherein R 9 is alkynyl substituted with an alkenyl, alkynyl, halogen, hydroxyl, alkylcarbonyloxy, arylcarbonyloxy, alkoxycarbonyloxy, aryloxycarbonyloxy, carboxylate, alkylcarbonyl, arylcarbonyl, alkoxycarbonyl, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, alkylthiocarbonyl, alkoxyl, phosphate, phosphonato, phosphinato, cyano, amino acylamino, amidino, imino, sulfhydryl, alkylthio, arylthio, thiocarboxylate, sulfates, alkylsulfinyl, sulfonato, sulfamoyl, sulfonamido, nitro, trifluoromethyl, cyano, azido, heterocyclyl, alkylaryl, or an aromatic or heteroaromatic moiety.
15. The minocycline compound of claim 1 , wherein said minocycline compound is of the formula:
16. The minocycline compound of claim 1 , wherein said minocycline compound is of the formula:
17. The minocycline compound of claim 1 , wherein said minocycline compound is of the formula:
18. The minocycline compound of claim 1 , wherein said minocycline compound is of the formula:
19. The minocycline compound of claim 1 , wherein said minocycline compound is of the formula:
20. The minocycline compound of claim 1 , wherein said minocycline compound is of the formula:
21. A method for treating a bacterial infection in a mammal, comprising administering to said subject an effective amount of a minocycline compound of any one of claims 1 , 6 , 7 or 15 - 20 , such that said subject is treated.
22. The method of claim 21 , wherein said bacterial infection is associated with E. coli.
23. The method of claim 21 , wherein said bacterial infection is associated with S. aureus.
24. The method of claim 21 , wherein said bacterial infection is associated with E. faecalis.
25. The method of claim 21 , wherein said bacterial infection is resistant to the other tetracycline antibiotics.
26. The method of claim 21 , wherein said minocycline compound is administered with a pharmaceutically acceptable carrier.
27. The method of claim 21 , wherein said subject is a human.
28. A pharmaceutical composition comprising a therapeutically effective amount of a minocycline compound of any one of claims 1 , 6 , 7 , or 15 - 20 and a pharmaceutically acceptable carrier.
29. A 9-substituted minocycline compound of the formula:
wherein:
R 4′ , R 4″ , R 7′ , and R 7″ are alkyl; and
R 9 is an alkynyl group, wherein said alkynyl group is substituted with an alkyl group pharmaceutically acceptable salts thereof.
30. A method for treating a bacterial infection in a subject, comprising administering to said subject an effective amount of a 9-substituted minocycline compound of claim 29 , such that said bacterial infection in said subject is treated.
31. The method of claim 78, wherein said bacterial infection is associated with E. coli, S. aureus , or E. faecalis.
32. The method of claim 30 , wherein said bacterial infection is resistant to other tetracycline antibiotics.
33. The method of claim 30 , wherein said compound is administered with a pharmaceutically acceptable carrier.
34. A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 29 and a pharmaceutically acceptable carrier.